In Table 1 of the Review “Engineering CAR-T therapies for autoimmune disease and beyond” by E. P. English et al., the sponsors of the clinical trials in the last section, “Engineered cell therapy studies in autoimmune diseases (non-BCMA or -CD19 targets),” were incorrect. The clinical trials and sponsors were originally listed as follows: NCT03605238, NCT05239702, and NCT06361836, Cabaletta Bio; NCT04422912, Tongji Hospital; NCT04561557, Zhejiang University; NCT05451212, Nanjing University School of Medicine; NCT06285279, Luminary Therapeutics; NCT06340750, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China; and NCT06352281, Sonoma Biotherapeutics, Inc. The clinical trials and sponsors are now correctly assigned as follows: NCT03605238, Chinese PLA General Hospital; NCT04422912 and NCT05451212, Cabaletta Bio; NCT04561557, Tongji Hospital; NCT05239702, Zhejiang University; NCT06285279, Nanjing University School of Medicine; NCT06340750, Luminary Therapeutics; NCT06352281, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China; and NCT06361836, Sonoma Biotherapeutics, Inc.
